Clinical Trial: Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024030) titled 'Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer' on May 18.

Brief Summary: a single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.

Study Start Date: Oct. 30, 2024

Study Type: INTERVENTIONAL

Condition: Prostate Cancer Patients Undergoing Radical Prostatectomy

Intervention: DRUG: 0.02mg/kg

Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the op...